Background: Intraductal papillary mucinous adenocarcinoma (IPMCs) occur more frequently in main-duct intraductal papillary mucinous neoplasms. Methods: Review of the literature. Results: The prognosis of IPMCs depends on its histopathological subtype: colloid IPMCs have superior survival rates mainly secondary to more favorable pathological features, whereas tubular IPMCs have survival outcomes similar to that of conventional pancreatic adenocarcinomas. The epithelial background plays an equally important role in defining the biology of IPMCs: gastric IPMC subtypes demonstrate an overall worse survival outcome when compared to intestinal, pancreatobiliary, and oncocytic subtypes. Lymph node involvement is one of the strongest predictors of survival in IPMC, with a decreasing overall survival as the lymph node ratio increases. There is little evidence to support adjuvant chemoradiation in patients with IPMC. Conclusion: Our current understanding of IPMC biology based on histopathological and epithelial background subtypes as well as clinicopathological predictors should influence patient counseling and selection for adjuvant therapy.

Keywords:
Intraductal papillary mucinous adenocarcinoma, Prognostic factors, Adjuvant therapy
1.
Valsangkar NP, Morales-Oyarvide V, Thayer SP, et al: 851 resected cystic tumors of the pancreas: a 33-year experience at the Massachusetts General Hospital. Surgery 2012;152(suppl 1):S4-12.
2.
Fernandez-del Castillo C, Targarona J, Thayer SP, et al: Incidental pancreatic cysts: clinicopathologic characteristics and comparison with symptomatic patients. Arch Surg 2003;138:427-433; discussion 433-434.
3.
Cauley CE, Waters JA, Dumas RP, et al: Outcomes of primary surveillance for intraductal papillary mucinous neoplasm. J Gastrointest Surg 2012;16:258-267; discussion 266.
4.
Kobari M, Egawa S, Shibuya K, et al: Intraductal papillary mucinous tumors of the pancreas comprise 2 clinical subtypes: differences in clinical characteristics and surgical management. Arch Surg 1999;134:1131-1136.
5.
Terris B, Ponsot P, Paye F, et al: Intraductal papillary mucinous tumors of the pancreas confined to secondary ducts show less aggressive pathologic features as compared with those involving the main pancreatic duct. Am J Surg Pathol 2000;24:1372-1377.
6.
Doi R, Fujimoto K, Wada M, et al: Surgical management of intraductal papillary mucinous tumor of the pancreas. Surgery 2002;132:80-85.
7.
Matsumoto T, Aramaki M, Yada K, et al: Optimal management of the branch duct type intraductal papillary mucinous neoplasms of the pancreas. J Clin Gastroenterol 2003;36:261-265.
8.
Kitagawa Y, Unger TA, Taylor S, et al: Mucus is a predictor of better prognosis and survival in patients with intraductal papillary mucinous tumor of the pancreas. J Gastrointest Surg 2003;7:12-18; discussion 18-19.
9.
Sugiyama M, Izumisato Y, Abe N, et al: Predictive factors for malignancy in intraductal papillary-mucinous tumours of the pancreas. Br J Surg 2003;90:1244-1249.
10.
Crippa S, Fernandez-Del Castillo C, Salvia R, et al: Mucin-producing neoplasms of the pancreas: an analysis of distinguishing clinical and epidemiologic characteristics. Clin Gastroenterol Hepatol 2010;8:213-219.
11.
Winter JM, Cameron JL, Campbell KA, et al: 1423 pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006;10:1199-1210; discussion 1210-1211.
12.
Fernandez-del Castillo C, Morales-Oyarvide V, McGrath D, et al: Evolution of the Whipple procedure at the Massachusetts General Hospital. Surgery 2012;152(suppl 1):S56-63.
13.
Sohn TA, Yeo CJ, Cameron JL, et al: Intraductal papillary mucinous neoplasms of the pancreas: an updated experience. Ann Surg 2004;239:788-797; discussion 797-799.
14.
D'Angelica M, Brennan MF, Suriawinata AA, et al: Intraductal papillary mucinous neoplasms of the pancreas: an analysis of clinicopathologic features and outcome. Ann Surg 2004;239:400-408.
15.
Yamaguchi K, Kanemitsu S, Hatori T, et al: Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN. Pancreas 2011;40:571-580.
16.
Yopp AC, Katabi N, Janakos M, et al: Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma. Ann Surg 2011;253:968-974.
17.
Mino-Kenudson M, Fernandez-del Castillo C, Baba Y, et al: Prognosis of invasive intraductal papillary mucinous neoplasm depends on histological and precursor epithelial subtypes. Gut 2011;60:1712-1720.
18.
Adsay NV, Merati K, Basturk O, et al: Pathologically and biologically distinct types of epithelium in intraductal papillary mucinous neoplasms: delineation of an ‘intestinal' pathway of carcinogenesis in the pancreas. Am J Surg Pathol 2004;28:839-848.
19.
Yopp AC, Allen PJ: Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas. World J Gastrointest Surg 2010;2:359-362.
20.
Partelli S, Fernandez-Del Castillo C, Bassi C, et al: Invasive intraductal papillary mucinous carcinomas of the pancreas: predictors of survival and the role of lymph node ratio. Ann Surg 2010;251:477-482.
21.
Yamada S, Fujii T, Shimoyama Y, et al: Clinical implication of morphological subtypes in management of intraductal papillary mucinous neoplasm. Ann Surg Oncol 2014;21:2444-2452.
22.
Miller JR, Meyer JE, Waters JA, et al: Outcome of the pancreatic remnant following segmental pancreatectomy for non-invasive intraductal papillary mucinous neoplasm. HPB (Oxford) 2011;13:759-766.
23.
Kang MJ, Jang JY, Lee KB, et al: Long-term prospective cohort study of patients undergoing pancreatectomy for intraductal papillary mucinous neoplasm of the pancreas: implications for postoperative surveillance. Ann Surg 2014;260:356-363.
24.
Chari ST, Yadav D, Smyrk TC, et al: Study of recurrence after surgical resection of intraductal papillary mucinous neoplasm of the pancreas. Gastroenterology 2002;123:1500-1507.
25.
Passot G, Lebeau R, Hervieu V, et al: Recurrences after surgical resection of intraductal papillary mucinous neoplasm of the pancreas: a single-center study of recurrence predictive factors. Pancreas 2012;41:137-141.
26.
Biankin AV, Biankin SA, Kench JG, et al: Aberrant p16(INK4A) and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma. Gut 2002;50:861-868.
27.
Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al: Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000;157:755-761.
28.
House MG, Guo M, Iacobuzio-Donahue C, et al: Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003;24:193-198.
29.
Yeo CJ, Abrams RA, Grochow LB, et al: Pancreaticoduodenectomy for pancreatic adenocarcinoma: postoperative adjuvant chemoradiation improves survival. A prospective, single-institution experience. Ann Surg 1997;225:621-633; discussion 633-636.
30.
Hsu CC, Herman JM, Corsini MM, et al: Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 2010;17:981-990.
31.
Alexander BM, Fernandez-Del Castillo C, Ryan DP, et al: Intraductal papillary mucinous adenocarcinoma of the pancreas: clinical outcomes, prognostic factors, and the role of adjuvant therapy. Gastrointest Cancer Res 2011;4:116-121.
32.
Swartz MJ, Hsu CC, Pawlik TM, et al: Adjuvant chemoradiotherapy after pancreatic resection for invasive carcinoma associated with intraductal papillary mucinous neoplasm of the pancreas. Int J Radiat Oncol Biol Phys 2010;76:839-844.
33.
Turrini O, Waters JA, Schnelldorfer T, et al: Invasive intraductal papillary mucinous neoplasm: predictors of survival and role of adjuvant therapy. HPB (Oxford) 2010;12:447-55.
34.
Maire F, Hammel P, Terris B, et al: Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma. Gut 2002;51:717-722.
35.
Sadakari Y, Ohuchida K, Nakata K, et al: Invasive carcinoma derived from the nonintestinal type intraductal papillary mucinous neoplasm of the pancreas has a poorer prognosis than that derived from the intestinal type. Surgery 2010;147:812-817.
© 2014 S. Karger GmbH, Freiburg
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.